Preclinical Development A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma

Abstract

Successwithmolecular-based targeteddrugs in the treatment of cancer has ignited extensive research efforts within the field of personalized therapeutics. However, successful application of such therapies is dependent on the presence or absence of mutations within the patient’s tumor that can confer clinical efficacy or drug resistance. Building on these… (More)

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Irwin2012PreclinicalDA, title={Preclinical Development A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma}, author={Darryl L Irwin and Priscilla Hunt and LaurenG. Aoude and Varsha Tembe and GuliettaM. Pupo and Cathy Lanagan and Candace D. Carter and Linda J O'connor and Michael O'Rourke and Richard A Scolyer and Graham J. Mann and Christopher William Schmidt and Adrian C. Herington and Nicholas Kim Hayward}, year={2012} }